Bridging science and health policy in cardiovascular disease: focus on lipid management A Report from a Session held during the 7th International Symposium on Multiple Risk Factors in Cardiovascular Diseases: Prevention and Intervention - Health Policy, in Venice, Italy, on 25 October, 2008

Research output: Contribution to journalArticle

Standard

Harvard

APA

Vancouver

Author

Bibtex

@article{50cebf344a1a46e089be3b4ec14bc050,
title = "Bridging science and health policy in cardiovascular disease: focus on lipid management A Report from a Session held during the 7th International Symposium on Multiple Risk Factors in Cardiovascular Diseases: Prevention and Intervention - Health Policy, in Venice, Italy, on 25 October, 2008",
abstract = "In Europe, cardiovascular disease (CVD) represents the main cause of morbidity and mortality, costing countries 190 billion yearly (2006). CVD prevention remains unsatisfactory across Europe largely due to poor control of CVD risk factors (RFs), growing incidence of obesity and diabetes, and sedentary lifestyle/poor dietary habits. Hypercholesterolaemia is a proven CVD RF, and LDL-C lowering slows atherosclerotic progression and reduces major coronary events. Lipid-lowering therapy is cost-effective, and intensive treatment of high-risk patients further improves cost effectiveness. In Italy, models indicate that improved cholesterol management translates into potential yearly savings of (sic) 2.9-4 billion. Identifying and eliminating legislative and administrative barriers is essential to providing optimal lipid care to high-risk patients. Public health and government policy can influence clinical practice rapidly, and guideline endorsement via national health policy may reduce the CVD burden and change physician and patient behaviour. Action to reduce CVD burden should ideally include the integration of strategies to lower the incidence of major CV events, improvement in total CV risk estimation, database monitoring of CVD trends, and development of population educational initiatives on CVD prevention. Failure to bridge the gap between science and health policy, particularly in relation to lipid management, could result in missed opportunities to reverse the burgeoning epidemic of CVD in Europe. (c) 2009 Elsevier Science Ireland Ltd. All rights reserved.",
keywords = "Government, Risk factors, Economics, LDL-C, Health policy, Cholesterol, Public health, Cardiovascular disease",
author = "V Atella and A Brady and AL Catapano and J Critchley and IM Graham and Frederick Hobbs and J Leal and P Lindgren and D Vanuzzo and M Volpe and D Wood and R Paoletti",
year = "2009",
month = jun,
day = "1",
doi = "10.1016/S1567-5688(09)70003-0",
language = "English",
volume = "10",
pages = "3--21",
journal = "Atherosclerosis. Supplements",
issn = "1567-5688",
publisher = "Elsevier",
number = "1",

}

RIS

TY - JOUR

T1 - Bridging science and health policy in cardiovascular disease: focus on lipid management A Report from a Session held during the 7th International Symposium on Multiple Risk Factors in Cardiovascular Diseases: Prevention and Intervention - Health Policy, in Venice, Italy, on 25 October, 2008

AU - Atella, V

AU - Brady, A

AU - Catapano, AL

AU - Critchley, J

AU - Graham, IM

AU - Hobbs, Frederick

AU - Leal, J

AU - Lindgren, P

AU - Vanuzzo, D

AU - Volpe, M

AU - Wood, D

AU - Paoletti, R

PY - 2009/6/1

Y1 - 2009/6/1

N2 - In Europe, cardiovascular disease (CVD) represents the main cause of morbidity and mortality, costing countries 190 billion yearly (2006). CVD prevention remains unsatisfactory across Europe largely due to poor control of CVD risk factors (RFs), growing incidence of obesity and diabetes, and sedentary lifestyle/poor dietary habits. Hypercholesterolaemia is a proven CVD RF, and LDL-C lowering slows atherosclerotic progression and reduces major coronary events. Lipid-lowering therapy is cost-effective, and intensive treatment of high-risk patients further improves cost effectiveness. In Italy, models indicate that improved cholesterol management translates into potential yearly savings of (sic) 2.9-4 billion. Identifying and eliminating legislative and administrative barriers is essential to providing optimal lipid care to high-risk patients. Public health and government policy can influence clinical practice rapidly, and guideline endorsement via national health policy may reduce the CVD burden and change physician and patient behaviour. Action to reduce CVD burden should ideally include the integration of strategies to lower the incidence of major CV events, improvement in total CV risk estimation, database monitoring of CVD trends, and development of population educational initiatives on CVD prevention. Failure to bridge the gap between science and health policy, particularly in relation to lipid management, could result in missed opportunities to reverse the burgeoning epidemic of CVD in Europe. (c) 2009 Elsevier Science Ireland Ltd. All rights reserved.

AB - In Europe, cardiovascular disease (CVD) represents the main cause of morbidity and mortality, costing countries 190 billion yearly (2006). CVD prevention remains unsatisfactory across Europe largely due to poor control of CVD risk factors (RFs), growing incidence of obesity and diabetes, and sedentary lifestyle/poor dietary habits. Hypercholesterolaemia is a proven CVD RF, and LDL-C lowering slows atherosclerotic progression and reduces major coronary events. Lipid-lowering therapy is cost-effective, and intensive treatment of high-risk patients further improves cost effectiveness. In Italy, models indicate that improved cholesterol management translates into potential yearly savings of (sic) 2.9-4 billion. Identifying and eliminating legislative and administrative barriers is essential to providing optimal lipid care to high-risk patients. Public health and government policy can influence clinical practice rapidly, and guideline endorsement via national health policy may reduce the CVD burden and change physician and patient behaviour. Action to reduce CVD burden should ideally include the integration of strategies to lower the incidence of major CV events, improvement in total CV risk estimation, database monitoring of CVD trends, and development of population educational initiatives on CVD prevention. Failure to bridge the gap between science and health policy, particularly in relation to lipid management, could result in missed opportunities to reverse the burgeoning epidemic of CVD in Europe. (c) 2009 Elsevier Science Ireland Ltd. All rights reserved.

KW - Government

KW - Risk factors

KW - Economics

KW - LDL-C

KW - Health policy

KW - Cholesterol

KW - Public health

KW - Cardiovascular disease

U2 - 10.1016/S1567-5688(09)70003-0

DO - 10.1016/S1567-5688(09)70003-0

M3 - Article

C2 - 19497553

VL - 10

SP - 3

EP - 21

JO - Atherosclerosis. Supplements

JF - Atherosclerosis. Supplements

SN - 1567-5688

IS - 1

ER -